



Media Release

11 April 2008

Annual General Meeting of Shareholders in Basel, Switzerland

ALLSCHWIL/BASEL, SWITZERLAND – 11 April 2008 – At today's Annual General Meeting of Actelion Ltd (SWX: ATLN), shareholders approved all resolutions.

Shareholders approved the annual report, including the financial statements, for the year 2007 and confirmed Ernst & Young to serve as the company's auditor for the year 2008.

The shareholders also re-elected Jean-Paul Clozel, Juhani Anttila and Carl Feldbaum to serve for an additional three years on the Actelion Board of Directors. The composition of the board, therefore, remains unchanged. The eight members are: Robert E. Cawthorn (Chairman), André J. Mueller (Vice-Chairman), Jean-Paul Clozel, Werner Henrich, Armin Kessler, Jean Malo, Juhani Anttila and Carl Feldbaum.

The Annual General Meeting of Actelion took place in Basel. It was attended by 225 shareholders, representing 48'620'320 shares or 39.56 percent of the total outstanding shares.

###

Actelion Ltd

Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN).

For further information please contact:

Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil

Roland Haefeli

Vice President, Head of Investor Relations & Public Affairs

+41 61 565 62 62

+1 650 624 69 36

<http://www.actelion.com>